161 related articles for article (PubMed ID: 26587992)
1. Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.
Ye P; Zhang M; Fan S; Zhang T; Fu H; Su X; Gavine PR; Liu Q; Yin X
PLoS One; 2015; 10(11):e0143207. PubMed ID: 26587992
[TBL] [Abstract][Full Text] [Related]
2. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
3. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
4. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
6. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
7. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
8. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
[TBL] [Abstract][Full Text] [Related]
9.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
10. Innovative personalized medicine in gastric cancer: time to move forward.
Lee J; Kim KM; Kang WK; Ou SH
Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer.
Gao J; Wang H; Zang W; Li B; Rao G; Li L; Yu Y; Li Z; Dong B; Lu Z; Jiang Z; Shen L
Cancer Sci; 2017 Sep; 108(9):1881-1887. PubMed ID: 28677165
[TBL] [Abstract][Full Text] [Related]
14. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
Deng N; Goh LK; Wang H; Das K; Tao J; Tan IB; Zhang S; Lee M; Wu J; Lim KH; Lei Z; Goh G; Lim QY; Tan AL; Sin Poh DY; Riahi S; Bell S; Shi MM; Linnartz R; Zhu F; Yeoh KG; Toh HC; Yong WP; Cheong HC; Rha SY; Boussioutas A; Grabsch H; Rozen S; Tan P
Gut; 2012 May; 61(5):673-84. PubMed ID: 22315472
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
17. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype.
Cruz-Reyes C; Gamboa-Dominguez A
Int J Surg Pathol; 2013 Jun; 21(3):240-6. PubMed ID: 23564704
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
Wang YK; Chen Z; Yun T; Li CY; Jiang B; Lv XX; Chu GH; Wang SN; Yan H; Shi LF
World J Gastroenterol; 2015 Apr; 21(15):4680-7. PubMed ID: 25914479
[TBL] [Abstract][Full Text] [Related]
19. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
Saito M; Yamashita K; Arimura Y; Kaneto H; Okuda H; Nojima M; Hagiwara T; Suzuki K; Adachi T; Goto A; Nakachi K; Yawata A; Yoshimoto M; Tanuma T; Adachi Y; Yamaoka S; Mizukoshi T; Kawayama M; Hamamoto Y; Shinomura Y
Acta Oncol; 2016; 55(3):309-17. PubMed ID: 26757197
[TBL] [Abstract][Full Text] [Related]
20. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
